Medical Devices

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

A Texas optometrist launches a new supplement aiming to fight dry eye and glare from the inside out. Can this clean-label formula change eye care?

Riding a wave of record sales from its iDose TR implant, Glaukos is set to update investors on its explosive growth and the launch of its new drug, Epioxa.

Zephyrus Innovations just got FDA clearance for VaporShield, a device protecting nurses from drug exposure. It’s a story of safety, market disruption, and efficiency.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A Chinese startup's tiny new heart pump enters human trials, aiming to disrupt a billion-dollar market and solve a massive unmet need in cardiac care.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

One firm is ditching market predictions for a new approach: debunking costly myths. Here’s why this matters for healthcare leaders and investors.

When a superstorm threatened a 10,000-person conference, one firm's crisis response offered a masterclass in resilience with lessons for the entire industry.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

A Minneapolis firm is testing a graft that helps the body rebuild its own arteries. This could end a painful, risky part of traditional heart bypass surgery.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

Beyond software, a new accelerator offers hardware startups a rare advantage, bridging the gap from university labs to investor-ready prototypes.